3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
2
Neoplasms
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Filgrastim
7
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Carboplatin
5
Temozolomide
4
Melphalan
4
Ifosfamide
4
Etoposide
4
Busulfan
4
Biopsy
4
Thiotepa
3
Peripheral Blood Stem Cell Transplantation
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Thalidomide
2
Paclitaxel
2
Mesna
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
Genistein
×
Genitourinary
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts